TG and TD parameters in the patients with APS (n = 33) and control participants (n = 62) in the neural network clinical validation cohort. (A-F) The TG lag time (A) and time-to-peak (C) were significantly prolonged in patients with APS, whereas the peak height (B), ETP (D), velocity index (E), and the effect of TM on the peak height were reduced (F); and time-to-peak (C) did not differ significantly between patients with APS and controls on VKA treatment; the ETP (D) was significantly lower in patients with APS than controls, whereas the velocity index (E) was significantly higher. (F) The inhibitory effect of TM was significantly less in patients with APS compared with controls. (G-K) TD parameters PC_tot (G), T-AT complex formation (J), and T-α2M formation (K) were significantly lower in patients with APS. (H) PC_max was significantly decreased in patients with APS, and the PC_max was less sensitive to the inhibitory actions of TM (I). (L) The thrombin decay capacity was significantly higher in patients with APS than controls. Differences between group means were analyzed using the Mann-Whitney test. ∗P < .05; ∗∗∗P < .001; ∗∗∗∗P < .0001. Data are shown as median and interquartile ranges.